HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cho, L. Articles by Lincoff, A. M. Search for Related Content PubMed PubMed Citation Articles by Cho, L. Articles by Lincoff, A. M.

Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender

Pooled analysis from EPIC, EPILOG and EPISTENT trials

Leslie Cho, MD^a, Eric J. Topol, MD, FACC^a, Craig Balog, BA^a, Joanne M. Foody, MD^a, Joan E. Booth, RN^a, Catherine Cabot, MD^*, Neal S. Kleiman, MD, FACC, James E. Tcheng, MD, FACC, Robert Califf, MD, FACC and A. Michael Lincoff, MD, FACC^a

^a Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
^* Centocor Incorporated, Cleveland, Ohio, USA
Baylor College of Medicine, Houston, Texas, USA
Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA

View larger version (17K): [in a new window]   Figure 1 Primary composite end point of death, MI or urgent revascularization at 30 days. p < 0.001 for both male and female patients. MI = myocardial infarction; Revasc = revascularization.

View larger version (16K): [in a new window]   Figure 2 Clinical predictors of outcome after percutaneous coronary revascularization for the overall cohort. HTN = hypertension; MI = myocardial infarction.

View larger version (17K): [in a new window]   Figure 3 Major and minor bleeding event rates for patients treated with abciximab. p = 0.004 for major bleeding event; p < 0.001 for minor bleeding events.

View larger version (13K): [in a new window]   Figure 4 Clincal predictors of bleeding complications using low-dose heparin arm of EPILOG and the entire EPISTENT cohort.